# US 2010/0168136 A1 · Alkylsulfone derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168136 A1
- Document ID: US20100168136A1
- Status: Published application
- Kind: A1
- Application number: 12/722,282
- Filed: 2010-03-11
- Published: 2010-07-01
- Earliest claimed: 2007-09-11
- Assignees: Daiichi Sankyo Company, Limited
- Inventors: Hitoshi Iimori; Hideki Kubota; Satoru Miyauchi; Kayoko Motoki
- Web page: https://patentgrep.com/patent/US20100168136A1

## CPC

- C07D 213/48: Aldehydo radicals
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/61: Halogen atoms or nitro radicals
- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/77: Hydrazine radicals
- C07D 213/79: Acids; Esters
- C07D 213/81: Amides; Imides
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound having activity to inhibit production and/or secretion of β-amyloid protein, and is useful for prevention and/or treatment of various diseases associated with abnormal production and/or secretion of β-amyloid protein, the compound represented by the general formula (I): [wherein, R1 represents a C1-C6 alkyl group which may have 1 to 6 halogen atoms as substituent groups, a C2-C6 alkenyl group which may have 1 to 6 halogen atoms as substituent groups, or a C3-C7 cycloalkyl group which may have 1 to 6 halogen atoms as substituent groups; R2 represents a 6-membered nitrogen-containing monocyclic aromatic heterocyclic group having 1 to 3 substituent groups, or a 9- or 10-membered nitrogen-containing bicyclic heterocyclic group having 1 to 4 substituent groups; Z1, Z2 and Z3 each independently represent a hydrogen atom, a halogen atom or a cyano group; and n represents 0, 1 or 2], salts thereof, or solvates thereof.

## Claims

### Claim 1

A compound represented by the general formula (I):
[wherein,
R1 represents a C1-C6 alkyl group which may have 1 to 6 halogen atoms as substituent groups, a C2-C6 alkenyl group which may have 1 to 6 halogen atoms as substituent groups, or a C3-C7 cycloalkyl group which may have 1 to 6 halogen atoms as substituent groups;
R2 represents a 6-membered nitrogen-containing monocyclic aromatic heterocyclic group having 1 to 3 substituent groups, or a 9- or 10-membered nitrogen-containing bicyclic heterocyclic group having 1 to 4 substituent groups;
Z1, Z2 and Z3 each independently represent a hydrogen atom, a halogen atom or a cyano group; and
n represents 0, 1 or 2],
salts thereof, or solvates thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, salts thereof, or solvates thereof, wherein R2 in the general formula (I) is any one of a group selected from the group consisting of a pyridyl group, a triazolopyridyl group and a pyridopyrimidinyl group, having 1 to 3 substituent groups.

### Claim 3 (depends on 1)

The compound according to claim 1, salts thereof, or solvates thereof, wherein R2 in the general formula (I) is a pyridyl group having 1 to 3 substituent groups.

### Claim 4 (depends on 1)

The compound according to claim 1, salts thereof, or solvates thereof, wherein R2 in the general formula (I) is a group represented by the following formula (1):
[wherein
Ra represents a halogen atom or a C1-C6 alkyl group; and Rb represents a carboxy C1-C6 alkyl group, a carbamoyl group, a N—C1-C6 alkylcarbamoyl group, a N,N-di(C1-C6 alkyl)carbamoyl group, a N-(hydroxy C1-C6 alkyl)carbamoyl group, a carboxy group, an amino group, a N-(hydroxy C1-C6 alkyl)amino group or a C1-C6 alkylsulfonylamino group].

### Claim 5 (depends on 4)

The compound according to claim 4, salts thereof, or solvates thereof, wherein Ra is a C1-C6 alkyl group and Rb is a N-(hydroxy C1-C6 alkyl)carbamoyl group in formula (1).

### Claim 6 (depends on 1)

The compound according to claim 1, salts thereof, or solvates thereof, wherein R2 in the general formula (I) is a group represented by the following formula (2):
[wherein
the group of nitrogen-containing ring structure represents a triazolopyridyl group or a pyridopyrimidinyl group; Rc represents a halogen atom or a C1-C6 alkyl group; Rd represents a hydrogen atom, a hydroxy group, an amino group, a N—(C1-C6 alkyl)amino group or a N-(hydroxy C1-C6 alkyl)amino group; and Re represents a hydroxy group or an oxo group].

### Claim 7 (depends on 1)

The compound according to claim 1, salts thereof, or solvates thereof, wherein R1 in the general formula (I) is a C1-C6 alkyl group which may have 1 to 6 halogen atoms as substituent groups.

### Claim 8 (depends on 1)

The compound according to claim 1, salts thereof, or solvates thereof, wherein R1 in the general formula (I) is a 2,2,2-trifluoroethyl group, a 2-chloro-2,2-difluoroethyl group, a 2,2-difluoropropyl group or a 2,2,3,3,3-pentafluoropropyl group.

### Claim 9 (depends on 1)

The compound according to claim 1, salts thereof, or solvates thereof, wherein Z1 and Z2 are both fluorine atoms and Z3 is a hydrogen atom, or Z1, Z2 and Z3 are each a fluorine atom, in the general formula (I).

### Claim 10 (depends on 1)

The compound according to claim 1, salts thereof, or solvates thereof, wherein n in the general formula (I) is 2.

### Claim at position 11

11-13. (canceled)

### Claim 14 (depends on 1)

A pharmaceutical composition containing the compound according to claim 1, salts thereof, or solvates thereof, and a pharmaceutically acceptable carrier.

### Claim at position 13

15-17. (canceled)

### Claim 18 (depends on 1)

A method for treating a disease associated with abnormal generation and/or secretion of β-amyloid protein, comprising administration of an effective amount of the compound according to claim 1, salts thereof, or solvates thereof.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the disease associated with abnormal generation and/or secretion of β-amyloid protein is Alzheimer's disease or Down's syndrome or the like.
